TRIALSITEIQ PUBLIC FEASIBILITY SCORECARD · GRADE D-

NCT06645120: ORIGIN-3: Phase 3 Trial of Atacicept Dual BAFF/APRIL Inhibitor in IgA Nephropathy (IgAN)

Sponsor: Vera Therapeutics, Inc. · Phase: PHASE3 · Area: IMMUNOLOGY · Target Enrollment: 376 pts

Competing Trials Overlap

8 Active Trials

Excess Burn Exposure

$13,864,170

Rescue Site Savings

+$9,161,130

Unlock Full NCT06645120 Backup Super-Site Packet ($49 One-Time Pass)

Download the complete list of top-decile low-cannibalization clinical sites, verified Principal Investigator (PI) direct emails/phones, and protocol optimization benchmarks.

Download $49 NCT06645120 Rescue Dossier →